Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Fatty Acid Binding Proteins Expressed at the Human Blood-Brain Barrier Bind Drugs in an Isoform-Specific Manner.

Lee GS, Kappler K, Porter CJ, Scanlon MJ, Nicolazzo JA.

Pharm Res. 2015 Oct;32(10):3432-46. doi: 10.1007/s11095-015-1764-5. Epub 2015 Aug 7.

PMID:
26248795
2.

A risk-based approach to managing active pharmaceutical ingredients in manufacturing effluent.

Caldwell DJ, Mertens B, Kappler K, Senac T, Journel R, Wilson P, Meyerhoff RD, Parke NJ, Mastrocco F, Mattson B, Murray-Smith R, Dolan DG, Straub JO, Wiedemann M, Hartmann A, Finan DS.

Environ Toxicol Chem. 2016 Apr;35(4):813-22. doi: 10.1002/etc.3163. Epub 2015 Nov 18. Review.

PMID:
26183919
3.

Jointly they edit: examining the impact of community identification on political interaction in Wikipedia.

Neff JJ, Laniado D, Kappler KE, Volkovich Y, Aragón P, Kaltenbrunner A.

PLoS One. 2013;8(4):e60584. doi: 10.1371/journal.pone.0060584. Epub 2013 Apr 3.

4.

The power laws of violence against women: rescaling research and policies.

Kappler KE, Kaltenbrunner A.

PLoS One. 2012;7(7):e40289. doi: 10.1371/journal.pone.0040289. Epub 2012 Jul 2.

5.

SFC/FTIR, SFC/APCI-MS and MALDI-TOF-MS for the analysis of siloxane-ethylene oxide copolymers.

Just U, Jones DJ, Auerbach RH, Davidson G, Käppler K.

J Biochem Biophys Methods. 2000 Jul 5;43(1-3):209-21.

PMID:
10869677
6.

A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.

McDermott DF, Trehu EG, Mier JW, Sorce D, Rand W, Ronayne L, Kappler K, Clancy M, Klempner M, Atkins MB.

Clin Cancer Res. 1998 May;4(5):1203-13.

7.

Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.

Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB.

J Clin Oncol. 1997 Mar;15(3):1052-62.

PMID:
9060545
8.

Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera.

Trehu EG, Mier JW, Dubois JS, Sorce D, Klempner MS, Epstein M, Dinarello CA, Shapiro L, Kappler K, Ronayne L, Atkins MB.

Clin Cancer Res. 1996 Aug;2(8):1341-51.

9.

Interleukin-6-associated anemia: determination of the underlying mechanism.

Atkins MB, Kappler K, Mier JW, Isaacs RE, Berkman EM.

Blood. 1995 Aug 15;86(4):1288-91.

10.

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.

Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI, et al.

J Clin Oncol. 1994 Aug;12(8):1553-60.

PMID:
8040667
12.

Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy.

Atkins MB, Vachino G, Tilg HJ, Karp DD, Robert NJ, Kappler K, Mier JW.

J Clin Oncol. 1992 Nov;10(11):1802-9.

PMID:
1403061

Supplemental Content

Loading ...
Support Center